Filspari is clinically suitable for adult patients with primary immunoglobulin A nephropathy (IgAN). It has the title of "orphan drug" for the treatment of IgA nephropathy. Many patients and their families will be concerned about what to pay attention to when taking Filspari. This will be introduced in detail below.
What should I pay attention to when taking Filspari?
Hypotension
To ensure the safety of patients with hypotensive tendencies, it is recommended to stop using endothelin receptor antagonists or replace them with other antihypertensive drugs, while maintaining the patient's appropriate blood volume to prevent further blood pressure drops. If the patient experiences hypotension during the use of sparsentan, the dosage of other antihypertensive drugs should be immediately stopped or reduced, and the dose of sparsentan should be considered to reduce the dose of sparsentan or temporarily stop the drug. After the patient's blood pressure stabilizes, gradually resume medication according to the doctor's guidance.
Acute renal injury
Patients should be extra cautious when using renin-angiotensin-aldosterone system inhibitors at the same time. Such drugs may induce acute renal injury and renal function should be monitored regularly during treatment. Once a significant decline in renal function of the patient is found, the risk must be evaluated immediately and the suspension of dosing or termination of treatment must be considered. Doctors should make judgments based on the patient's specific circumstances to avoid further damage to renal function by the drug.
Patients need to use sparsentan under the doctor's prescription and medication advice. Follow the doctor's advice and contact the doctor in time if there is discomfort during the medication process so that the medication plan and dosage can be adjusted.
What are the taboo groups of Filspari?
Many patients are more concerned about the taboo population of Filspari and whether they are among the taboo population of Filspari. This will be introduced in detail below.
Prohibited for pregnant women
Sparsentan is a special drug. To ensure the health and safety of the fetus, pregnant women should strictly prohibit the use of Sparsentan. If you get pregnant unexpectedly during treatment, you should immediately stop taking medication and consult a doctor for further evaluation and treatment.
Contraindications for combined use of drugs
During the treatment process, Sparsentan is prohibited from being combined with drugs such as renin-angiotensin-aldosterone system (RAAS) inhibitors, endothelin receptor antagonists (ERAs), and aliskiren. This is because these drugs may interact with Sparsentan in their mechanism of action, resulting in an increase in adverse reactions or a weakening of therapeutic effect. Doctors should pay special attention to this when prescribing.
When purchasing medicines, be sure to ensure the formality of the purchasing channels. It is recommended to choose a reputable regular pharmacy or medical institution to purchase it to ensure the quality of the medicine. Avoid purchasing drugs of unknown origin to avoid encountering counterfeit and inferior products and harming health. Choose formal channels with caution.
